About Prolaio
Prolaio is a cardiovascular health technology company that has developed a clinical intelligence platform designed to transform heart care through continuous, high-density data collection and analysis. The company's platform integrates medical insights and data analytics to improve the efficiency, quality, and success probability of cardiovascular clinical development. Using clinical-grade wearable sensors, Prolaio captures physiologic data including pulse, respiration, activity, and electrocardiogram continuously during patients' daily lives, rather than relying on episodic clinic-based assessments. Data collected by mobile relay devices are securely streamed to Prolaio's cloud environment where proprietary AI-based algorithms analyze the information to generate measures of cardiovascular function and capacity. The company serves patients, healthcare providers, and clinical researchers across 22+ countries, with a particular focus on accelerating drug development and enabling precision cardiology. Prolaio has developed FDA-cleared algorithms including eVO2peak, which provides CPET-level cardiopulmonary insights remotely without requiring patients to complete strenuous exercise tests. The company was co-founded by Tassos Gianakakos and operates in partnership with Kardigan, a cardiovascular therapeutics company, to create an integrated approach combining real-world data with drug development. Prolaio's mission is to transform real-world heart data into faster discovery and precision care for functional cures, with the ultimate goal of eradicating avoidable heart conditions.
Mission & Story
Mission
Unlocking continuous, predictive and shareable heart data to liberate patients from hospital-based reactive care and accelerate every new therapy. We aim to transform real-world heart data into faster discovery today and precision care for functional cures tomorrow.
Founding Story
Prolaio was co-founded by Tassos Gianakakos, who also co-founded Kardigan, a cardiovascular therapeutics company. Both companies were founded to challenge the status quo in cardiology by fundamentally embracing real-world data and AI-based tools integrated across R&D. The founding vision was to radically reduce the time and cost to develop meaningful new medicines and provide better healthcare access and outcomes for patients.
Clinical Focus
Medical conditions and clinical areas addressed by Prolaio.
Who It Serves
Milestones & Awards
Recent Milestones
Recent FDA 510(k) clearance for eVO2peak algorithm; ISO 13485:2016 and MDSAP certification achieved; Strategic combination announced with Kardigan to create integrated heart health company
Awards & Recognition
Best Places to Work 2026, World's Top HealthTech Companies of 2025
Key Partnerships
Company Details
- Headquarters
- Chicago, IL, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.